Results 281 to 290 of about 197,362 (384)

Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies

open access: yesEpilepsia, EarlyView.
Abstract Drug development for developmental and epileptic encephalopathies (DEEs) follows different strategies on one hand including disease‐targeting precision medicine approaches considering the genetic variants and pathomechanisms in DEEs and on the other hand including therapeutic approaches with novel targets or second‐generation drug candidates ...
Heidrun Potschka, Daniel Pérez‐Pérez
wiley   +1 more source

First‐in‐class inhibitors of SbnA reduce siderophore production in Staphylococcus aureus

open access: yesThe FEBS Journal, EarlyView.
The production of the iron‐chelating compound staphyloferrin B by the most invasive S. aureus strains is crucial for colonization, virulence, and survival in the host. Staphyloferrin B biosynthesis is carried out by eight enzymes, the Sbn system, that offer an appealing source of potential targets for the development of antimicrobials.
Sarah Hijazi   +15 more
wiley   +1 more source

The association between HIV drug resistance testing, viral suppression and mortality in Ontario: a retrospective cohort study

open access: yesHIV Medicine, EarlyView.
Abstract Background Drug resistance compromises the effectiveness of antiretroviral therapy (ART). Resistance testing prior to initiating therapy is recommended in guidelines in many high‐income countries, and it has been shown to improve outcomes after first‐line ART regimen failure. There is limited evidence on its role in treatment‐naïve individuals.
Lawrence Mbuagbaw   +15 more
wiley   +1 more source

Chemical reactivity of RNA and its modifications with hydrazine. [PDF]

open access: yesCommun Chem
Yeşiltaç-Tosun N   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy